Key Takeaways
- Jim Cramer advised investors to avoid purchasing stocks experiencing “parabolic” surges in tech and AI sectors due to rapid reversals
- Superior investment prospects can be found in undervalued, overlooked equities currently out of favor
- Cramer’s Charitable Trust acquired Johnson & Johnson positions during the stock’s decline
- He identified J&J as his top pharmaceutical pick, surpassing Eli Lilly, based on pipeline strength and company restructuring
- Cramer emphasized maintaining balanced exposure across both trending and underperforming sectors
During Monday’s broadcast of CNBC’s Mad Money, Jim Cramer urged investors to redirect their attention away from the market’s soaring winners and toward overlooked opportunities.
Cramer described stocks experiencing “parabolic” trajectories, particularly within technology and artificial intelligence, as risky acquisitions. He acknowledged his own history of losses when purchasing during such dramatic upswings.
“Those are all too hot, hot, hot for me,” Cramer said, referring to high-flying semiconductor and AI names.
Rather than pursuing momentum plays in companies like Intel or Advanced Micro Devices, Cramer revealed he’s implementing a contrarian approach. He’s targeting high-quality corporations that have experienced selloffs and lost market favor.
His CNBC Investing Club Charitable Trust recently accumulated shares of Johnson & Johnson during the stock’s continued descent. Healthcare currently ranks as the S&P 500’s weakest sector performance in 2025.
“We are buying it in freefall,” Cramer said. “You don’t get to buy the best at a discount very often. When you do, you buy some.”
Cramer’s Rationale Behind the Johnson & Johnson Position
Cramer designated Johnson & Johnson as his leading pharmaceutical investment, displacing Eli Lilly from that position. He pointed to the company’s developmental pipeline and strategic business overhaul as primary factors driving his conviction.
Johnson & Johnson has actively divested underperforming business units while intensifying its pharmaceutical research focus. The corporation maintains numerous candidates in advanced development stages alongside several recently approved products.
Cramer attributed the stock’s recent weakness primarily to peripheral concerns, especially litigation surrounding talc-related lawsuits. He maintained these worries have obscured genuine operational improvements within the organization.
He also flagged a pattern with Johnson & Johnson earnings. The stock often gets sold off when results first come out in the morning, then recovers once the conference call begins. “If it gets blasted, try to get some,” he said.
Building a Balanced Portfolio Approach
Cramer’s overarching message centered on portfolio construction methodology. He warned that concentration in trending sectors creates vulnerability because market sentiment shifts rapidly.
“Your portfolio always needs to have a decent mix between what’s hot and what’s not,” he said.
When specific market segments lose momentum, maintaining positions in undervalued companies ensures continued portfolio performance. Cramer credited this principle to lessons learned during his time at Goldman Sachs.
“They don’t all go up at once. To which I always said, but something should go up.”
Healthcare equities have faced significant headwinds throughout 2025. Johnson & Johnson shares have declined over the trailing twelve months, with the stock dropping approximately 1.57% in recent trading sessions amid persistent sector-wide pressure.
